Literature DB >> 20855098

UL84-independent replication of human cytomegalovirus strain TB40/E.

David J Spector1, Kristen Yetming.   

Abstract

The UL84 gene of human cytomegalovirus is implicated in the initiation of viral DNA replication during lytic infection. UL84 is essential for replication of a cloned viral origin of lytic replication (oriLyt) in vitro and mutants of strains AD169 or Towne with deletions or insertions in UL84 fail to grow in cells permissive for wild type virus. Here we show that UL84 is dispensable for replication of a strain TB40/E clone derived from a bacterial artificial chromosome. The genomes of the fibroblast-adapted strains AD169 and Towne are altered substantially from the consensus for strains that have not been propagated extensively in cell culture. The parental TB40/E genome conforms to the consensus genomic organization. Accordingly, natural HCMV strains may possess replication capability that extends beyond the known oriLyt-dependent replication system of laboratory strains.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20855098     DOI: 10.1016/j.virol.2010.08.029

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Human Cytomegalovirus Utilizes Extracellular Vesicles To Enhance Virus Spread.

Authors:  Nicholas T Streck; Yuanjun Zhao; Jeffrey M Sundstrom; Nicholas J Buchkovich
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

2.  Differential Requirement of Human Cytomegalovirus UL112-113 Protein Isoforms for Viral Replication.

Authors:  Tim Schommartz; Jiajia Tang; Rebekka Brost; Wolfram Brune
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

3.  A mutation deleting sequences encoding the amino terminus of human cytomegalovirus UL84 impairs interaction with UL44 and capsid localization.

Authors:  Blair L Strang; Brian J Bender; Mayuri Sharma; Jean M Pesola; Rebecca L Sanders; Deborah H Spector; Donald M Coen
Journal:  J Virol       Date:  2012-08-01       Impact factor: 5.103

4.  Human Cytomegalovirus Decreases Major Histocompatibility Complex Class II by Regulating Class II Transactivator Transcript Levels in a Myeloid Cell Line.

Authors:  Praneet K Sandhu; Nicholas J Buchkovich
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

5.  Nonenvelopment Role for the ESCRT-III Complex during Human Cytomegalovirus Infection.

Authors:  Nicholas T Streck; Jillian Carmichael; Nicholas J Buchkovich
Journal:  J Virol       Date:  2018-05-29       Impact factor: 5.103

6.  Human cytomegalovirus latency alters the cellular secretome, inducing cluster of differentiation (CD)4+ T-cell migration and suppression of effector function.

Authors:  Gavin M Mason; Emma Poole; J G Patrick Sissons; Mark R Wills; John H Sinclair
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-23       Impact factor: 11.205

7.  Cis and trans acting factors involved in human cytomegalovirus experimental and natural latent infection of CD14 (+) monocytes and CD34 (+) cells.

Authors:  Cyprian C Rossetto; Margaret Tarrant-Elorza; Gregory S Pari
Journal:  PLoS Pathog       Date:  2013-05-23       Impact factor: 6.823

8.  Latency-associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection.

Authors:  Michael P Weekes; Shireen Y L Tan; Emma Poole; Suzanne Talbot; Robin Antrobus; Duncan L Smith; Christina Montag; Steven P Gygi; John H Sinclair; Paul J Lehner
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

9.  Regulation of host and viral promoters during human cytomegalovirus latency via US28 and CTCF.

Authors:  Elizabeth G Elder; Benjamin A Krishna; Emma Poole; Marianne Perera; John Sinclair
Journal:  J Gen Virol       Date:  2021-05       Impact factor: 5.141

10.  Depletion of cellular pre-replication complex factors results in increased human cytomegalovirus DNA replication.

Authors:  Tamara Evans Braun; Emma Poole; John Sinclair
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.